We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.38%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.47B
AUM Growth
+$39M
Cap. Flow
-$32.3M
Cap. Flow %
-2.19%
Top 10 Hldgs %
26.19%
Holding
101
New
9
Increased
29
Reduced
33
Closed
7

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$21.4M
2
PFE icon
Pfizer
PFE
+$19.4M
3
VEEV icon
Veeva Systems
VEEV
+$17.8M
4
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$11.9M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$11.6M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13M
3
LIVN icon
LivaNova
LIVN
+$11.9M
4
NVCR icon
NovoCure
NVCR
+$11.7M
5
CNC icon
Centene
CNC
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 94.98%
2 Industrials 1.94%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
101
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-40,000
Closed -$6.12M
1 2 3 4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Rhenman & Partners Asset Management held 101 positions worth $1.47B, up 2.7% from $1.43B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management's Q2 2021 filing shows 9 new, 29 increased, 33 reduced and 7 closed positions. Its largest new stake was Pfizer: 500,000 shares worth $19.6M. The largest sale was Johnson & Johnson, an estimated $41.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Rhenman & Partners Asset Management's largest Q2 2021 buy was Pfizer: 500,000 shares worth $19.6M.
  • Rhenman & Partners Asset Management added most to Biogen in Q2 2021, an estimated $21.4M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2021 reduction was Johnson & Johnson, cutting an estimated $41.4M.
  • Rhenman & Partners Asset Management fully exited Adverum Biotechnologies in Q2 2021, selling an estimated $6.41M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $1.47B portfolio in Q2 2021.
  • Rhenman & Partners Asset Management opened 9 new positions and closed 7 in Q2 2021.
  • Rhenman & Partners Asset Management's portfolio value rose 2.7% quarter-over-quarter to $1.47B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.